Back to today’s briefing

Story perspectives

Coave Therapeutics Raises €32 Million for Genetic Innovation

1/17/2025

41 9

Summary

Story summary

Coave Therapeutics has secured €32 million ($33 million) in Series A funding, spearheaded by Novo Holdings and Bpifrance. This investment will bolster their ALIGATER platform, revolutionizing genetic payload delivery to critical tissues. With a focus on tackling central nervous system, neuromuscular, and eye diseases, Coave is gearing up for clinical studies in 2026, promising hope for patients.

1 of 1

Story summary

Coave Therapeutics has secured €32 million ($33 million) in Series A funding, spearheaded by Novo Holdings and Bpifrance. This investment will bolster their ALIGATER platform, revolutionizing genetic payload delivery to critical tissues. With a focus on tackling central nervous system, neuromuscular, and eye diseases, Coave is gearing up for clinical studies in 2026, promising hope for patients.